≡

Multiplex Assay Kit for Biglycan (BGN) ,etc. by FLIA (Flow Luminescence Immunoassay)

DSPG1; PG-S1; PGI; SLRR1A; Biglycan Proteoglycan; Bone/cartilage proteoglycan I

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Biglycan (BGN) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Biglycan (BGN) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Biglycan (BGN) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Biglycan (BGN) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 85-92 89
EDTA plasma(n=5) 96-104 99
heparin plasma(n=5) 85-95 89

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Biglycan (BGN) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Biglycan (BGN) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Biglycan (BGN) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 90-105% 84-104% 89-96% 80-92%
EDTA plasma(n=5) 89-96% 89-101% 90-99% 96-105%
heparin plasma(n=5) 87-94% 78-91% 79-102% 81-90%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:BGN) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Sci Rep.  Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysreCavia (Guinea pig )lation of biglycan Pubmed:27295191
Cell Death & Disease Tenomodulin is essential for prevention of adipocyte accumulation and fibrovascular scar formation during early tendon healing. pubmed:29022912
Diabetes & Vascular Disease Research Degenerative aortic valve disease and diabetes: Implications for a link between proteoglycans and diabetic disorders in the aortic valve Pubmed: 30563371
博士论文 Die Rolle der extrazellulären Matrix in der degenerativen Aortenklappenerkrankung unter dem Einfluss von Diabetes
J Transl Med Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans 33407555
researchsquare Inhibition of Stromal Biglycan Promotes Normalization of the Tumor Microenvironment and Enhances Chemotherapeutic Efficacy 33966638
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPJ226Hu01 Recombinant Biglycan (BGN) Positive Control; Immunogen; SDS-PAGE; WB.
APJ226Hu03 Active Biglycan (BGN) Cell culture; Activity Assays.
RPJ226Hu03 Recombinant Biglycan (BGN) Positive Control; Immunogen; SDS-PAGE; WB.
RPJ226Hu02 Recombinant Biglycan (BGN) Positive Control; Immunogen; SDS-PAGE; WB.
PAJ226Hu01 Polyclonal Antibody to Biglycan (BGN) WB; IHC; ICC; IP.
PAJ226Hu02 Polyclonal Antibody to Biglycan (BGN) WB; IHC; ICC; IP.
LAJ226Hu71 Biotin-Linked Polyclonal Antibody to Biglycan (BGN) WB; IHC; ICC.
SEJ226Hu ELISA Kit for Biglycan (BGN) Enzyme-linked immunosorbent assay for Antigen Detection.
LMJ226Hu Multiplex Assay Kit for Biglycan (BGN) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.